Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7270911 | 0.80 | CHRNB4 (0.47) | CHRM1 | |
| SCHEMBL1797593 | 0.75 | CHRNB4 (0.50) | — | |
| SCHEMBL1797592 | 0.75 | CHRNB4 (0.50) | — | |
| SCHEMBL6819282 | 0.75 | CHRNB4 (0.50) | — | |
| SCHEMBL10905608 | 0.74 | CHRNB4 (0.47) | — | |
| SCHEMBL13403259 | 0.74 | CHRNB4 (0.49) | — | |
| SCHEMBL23415178 | 0.72 | CYP2D6 (0.72) | CYP1A2CYP2D6HIF1ALMNA | |
| SCHEMBL30136172 | 0.72 | CYP2D6 (0.72) | CYP1A2CYP2D6HIF1ALMNA | |
| SCHEMBL3309738 | 0.72 | CYP2D6 (0.72) | CYP1A2CYP2D6HIF1ALMNA | |
| SCHEMBL26731759 | 0.71 | CHRNB4 (0.56) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6943177-B2 | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2005-09-13 | — | — | US | claimed |
| US-20040266824-A1 | 2,6-disubstituted piperidines and piperazine compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2004-12-30 | — | — | US | claimed |
| US-7368443-B2 | 2,6-disubstituted piperidines and piperazine compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2008-05-06 | — | — | US | disclosed |
| US-6943177-B2 | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040266824-A1 | 2,6-disubstituted piperidines and piperazine compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2004-12-30 | — | — | US | disclosed |
| US-20030100547-A1 | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100547-A1 | Cis-2,6-disubstituted piperidines for the treatment of psychostimulant abuse and withdrawal, eating disorders, and central nervous system diseases and pathologies | SLC1A2, PNMT, SLC18A2 | CHRM1 141/4885CYP1A2 161/4885CYP2D6 628/4885 |
| US-20040266824-A1 | 2,6-disubstituted piperidines and piperazine compounds | GRM5, GRM6, SLC1A2 | CHRM1 1387/4885CYP1A2 184/4885CYP2D6 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.